Veeva Systems announced it has acquired Copli, the pioneer in agentic medical, legal, and regulatory (MLR) solutions for the life sciences industry. Copli is now available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years. The acquisition terms were not disclosed. The strategic move aims to address the bottleneck in getting critical information to patients and doctors by speeding up the entire review cycle.

Veeva Falcon MLR brings agentic automation to marketing teams, MLR groups, and agencies. It executes rigorous reviews of promotional and medical materials, conducting compliance checks against approved labels and local regulations. This automation minimizes manual effort and allows reviewers to focus on higher value work.

Jacob Scheel-Bech, CEO of Copli, stated that the breakthrough with agentic MLR marks a fundamental shift in commercial and medical content review and approval. He noted that as part of Veeva, the company can scale its vision for MLR transformation, bringing compliance at speed to the industry with intelligent agents that work seamlessly with Veeva PromoMats.

Emma Hyland, vice president, Veeva Commercial Content, highlighted that the MLR process has long been a significant bottleneck. She explained that with Veeva Falcon MLR, customers can automate routine labor so reviewers can become strategic advisors.

UCB is unifying its global safety operations with Veeva Safety Suite to maximize operational efficiency and scale. The company is standardizing safety on a single platform to accelerate case processing, strengthen oversight, and streamline submissions to health authorities. This strategic move aims to establish a single source of truth for safety data.

"Moving our teams onto Veeva Safety Suite is a core step in UCB's safety transformation, helping streamline global and local workflows with a single source of truth for safety data," said Jonas Maselis, head of digital technology, patient safety, UCB. "As we use automation to drive low-touch case processing, our strategic partnership with Veeva positions us well for what's next."

The implementation involves several components of the Veeva Safety Suite. UCB will use Veeva Safety to streamline the intake, processing, and submission of adverse events. Veeva SafetyDocs will manage all safety-related content and processes. Additionally, Veeva Safety Workbench will enable advanced data analysis for fast, scalable reporting, while Veeva Safety Signal will automate signal detection for better visibility and alignment across the organization.

To ensure data consistency, the Veeva Safety-RIM Connection will share product information automatically across regulatory and safety operations. This integration is designed to provide clean and trusted data throughout the company's systems.

"UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function," said John Lawrie, vice president, Veeva Safety. "With a unified and connected approach, UCB is enhancing global compliance and driving advanced automation to deliver safe and effective medicines to patients."

Key Components of Veeva Safety Suite